VASH2 and pancreatic neoplasm: VASH2 increased the expression of ZEB1/2 in pancreatic tumors through activation of the SHH pathway, which both facilitated the EMT process and increased the resistance of pancreatic tumors to gemcitabine chemotherapy23.